Basilea Pharmaceutica (LTS:0QNA) Change In Inventory: CHF-3.4 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QNA Basilea Pharmaceutica Ltd LTS:0QNA
61 GF Score
Price CHF66.20
GF Value CHF57.72
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Change In Inventory?

Basilea Pharmaceutica LTS:0QNA +2.24% 61 Change In Inventory is CHF-3.4 Mil as of Jun. 2026. GuruFocus rates LTS:0QNA with a GF Score™ of 61/100 and a GF Value™ of CHF57.72 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Basilea Pharmaceutica's change in inventory for the quarter that ended in Jun. 2026 was CHF-4.5 Mil. It means Basilea Pharmaceutica's inventory increased by CHF4.5 Mil from Dec. 2025 to Jun. 2026 .

Basilea Pharmaceutica's change in inventory for the fiscal year that ended in Dec. 2025 was CHF10.1 Mil. It means Basilea Pharmaceutica's inventory declined by CHF10.1 Mil from Dec. 2024 to Dec. 2025 .

Basilea Pharmaceutica's Total Inventories for the quarter that ended in Jun. 2026 was CHF26.0 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Basilea Pharmaceutica's Days Inventory for the quarter that ended in Jun. 2026 was 281.49.

Inventory Turnover measures how fast the company turns over its inventory within a year. Basilea Pharmaceutica's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.65.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Basilea Pharmaceutica's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.20.

Basilea Pharmaceutica  (LTS:0QNA) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Basilea Pharmaceutica's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=23.798/15.429*365 / 2
=281.49

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Basilea Pharmaceutica's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=15.429 / 23.798
=0.65

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Basilea Pharmaceutica's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=23.798 / 118.996
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Change In Inventory Related Terms

Basilea Pharmaceutica Change In Inventory Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Change In Inventory Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.59 -1.46 -2.17 -5.20 10.05

Basilea Pharmaceutica Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.97 -0.23 8.98 1.07 -4.48
LTS:0QNA
61GF Score
Basilea Pharmaceutica Ltd LTS:0QNA
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-3.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of CHF-3.4 Mil mean?
Basilea Pharmaceutica (LTS:0QNA) has a Change In Inventory of CHF-3.4 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Change In Inventory too high?
Basilea Pharmaceutica's current Change In Inventory is CHF-3.4 Mil. Overall, Basilea Pharmaceutica has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Change In Inventory compare to VRTX and REGN?
Basilea Pharmaceutica's Change In Inventory of CHF-3.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Change In Inventory is CHF-3.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (LTS:0QNA) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF57.72, compared to a current price of CHF66.20 — trading 14.7% above its estimated fair value. The current Change In Inventory is CHF-3.4 Mil. Basilea Pharmaceutica's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Basilea Pharmaceutica (LTS:0QNA), the current Change In Inventory is CHF-3.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (LTS:0QNA) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be overvalued. The current stock price of CHF66.20 is trading 14.7% above its estimated GF Value™ of CHF57.72. GuruFocus considers Basilea Pharmaceutica to be Modestly Overvalued.

Key valuation signals for LTS:0QNA:

  • Change In Inventory: CHF-3.4 Mil
  • GF Value™: CHF57.72 vs. price of CHF66.20 (14.7% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the LTS:0QNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
61GF Score

Get the complete analysis for LTS:0QNA

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF66.20
Price
CHF57.72
GF Value